Prostate cancer: current status Prostate cancer (PCa) is the most common non-cutaneous
malignancy in men and is responsible for the second most common age-adjusted death rate …

Prostate cancer is perhaps the only cancer type in which biomarkers have changed the
clinical course of the disease. As recently as 20 years ago, more than half of the men …

Prostate cancer (PCa) is the second most prevalent cancer in men. In 2020, approximately
1,414,259 new cases were reported that accounted for 3, 75,324 deaths (Sung et al. in CA …

Along with significant advances in prostate cancer biology research, we also observe the
rapid development of modern diagnostic tests. New biomarkers are derived to detect …

The prevalence of prostate cancer (PCa) is high and increases with age. PCa is the most
common noncutaneous cancer in American men, with an estimate of 192,280 new cases …

Traditionally, diagnosis and staging of prostate cancer (PCa) have been based on prostate-
specific antigen (PSA) level, digital rectal examination (DRE), and transrectal ultrasound …

Prostate cancer (PCa) is the most commonly diagnosed solid tumor among men in the
United States and Europe. Even without treatment, PCa-specific mortality rates at 5 and 10 …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

BIOMARKERS for prostate cancer detection have never been more controversial. Recent
recommendations from the United States Preventive Task Force and revised American …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …